Saffron has more evidence behind it than most mood supplements — and the picture that emerges is genuinely mixed, not a simple yes. Two recent pieces of research, looked at together, give a fuller and more honest read than either does alone.
The broad view comes from a meta-analysis pooling 34 randomized controlled trials, 1769 participants in total. On the Beck Depression Inventory (14 trials, 817 participants), saffron supplementation produced WMD = -4.39 (p < 0.001) versus placebo. On the Beck Anxiety Inventory (6 trials, 339 participants), the effect was WMD = -5.06 (p = 0.003). But when researchers checked clinician-rated scales instead of self-report — the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and a separate mood questionnaire (POMS) — the effect disappeared. Nothing significant showed up. The certainty of this evidence was rated moderate by the review's own GRADE assessment, and heterogeneity between the 34 trials was high (I2 up to 94.8%), meaning results varied a lot from study to study.
The largest single trial to date adds a sharper, more specific picture. Two hundred and two adults with low mood took either 28 mg of a saffron extract (Affron) or a placebo daily for 12 weeks. The saffron group's depression scores improved significantly more than placebo (Cohen's d = 0.39, a small-to-moderate effect), and 72.3% of the saffron group reached a clinically meaningful improvement, compared with 54.3% on placebo. Sleep problems only improved in the subset of participants who started out with more severe sleep disturbance (Cohen's d = 0.44 in that subgroup) — there was no broad sleep benefit across the whole group. No serious side effects were reported.
Here's the catch worth being upfront about. That 202-person trial was funded by Pharmactive Biotech, the company that manufactures the Affron extract tested — two of the five authors are employees of the sponsor. It's still a real randomized, placebo-controlled trial, not a marketing claim, but it's the kind of funding link that's fair to know before treating a single study as the final word. The meta-analysis, by contrast, pooled trials from many different sources and declared no funding conflict.
Put together, a consistent story emerges. Saffron seems to move the needle on how people feel — self-reported mood and anxiety improve fairly reliably across dozens of trials. What's much less clear is whether it changes what a clinician would measure as depression or anxiety severity, where the evidence is thinner and, in the biggest pooled analysis, not statistically significant at all. Sleep benefits, where they show up, seem limited to people who already have notably disrupted sleep.
Bottom line. Saffron has real evidence for improving self-reported mood and anxiety symptoms — including from the largest trial run so far, at 28 mg per day for 12 weeks — but it has not been shown to reliably move clinician-rated depression or anxiety scores, and the strongest single-trial result comes with a manufacturer funding link worth factoring in. It looks like a reasonable complementary option to discuss with a doctor, not a replacement for established treatment.
Medical note. This article is for general education purposes only and is not intended as personal medical advice.